This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 28, 2006
Last updated: October 25, 2012
Last verified: October 2012
The main purpose of this study is to compare how one 50mg tablet of SB-497115 is broken down in the body by healthy subjects versus subjects with mild, moderate or severe liver problems. The study is also being done to 1) check on how well the study drug is tolerated by healthy subjects versus those with liver problems and 2) to check if liver impairment affects how the study drug binds to protein in the blood.

Condition Intervention Phase
Hepatic Impairment Purpura, Thrombocytopenic, Idiopathic Drug: eltrombopag Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Non-Randomized Pharmacokinetic and Safety Study of a Single Oral Dose of 50mg Eltrombopag in Healthy Subjects and in Volunteers With Mild, Moderate or Severe Hepatic Impairment

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Plasma levels and protein binding of eltrombopag [ Time Frame: Day 1 to Day 6 ]

Secondary Outcome Measures:
  • Safety will be monitored by: - clinical lab tests - vital signs - electrocardiograms - monitoring for adverse events - physical exams - eye exams [ Time Frame: throughout the study ]

Enrollment: 32
Study Start Date: April 2006

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Healthy or have liver impairment
  • Females(the following requirement applies only if able to have children): agree to doctor approved birth control methods, or partner has had a vasectomy.
  • Body mass index (BMI-within acceptable range)
  • Negative drug, alcohol, and HIV tests

Exclusion criteria:

  • Taking a medication or therapy not approved by the study doctor
  • Rapidly changing liver function
  • Kidneys not working well
  • Drug or alcohol abuse within past 6 months
  • Used an investigational drug in the past 30 days
  • Females that are pregnant or nursing
  • Have active hepatitis B or C
  • History of blood disorders
  • History of various heart conditions (as noted by study doctor)
  • Blood clotting problems or blood abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00359463

United States, Florida
GSK Investigational Site
Gainesville, Florida, United States, 32608
GSK Investigational Site
Orlando, Florida, United States, 32809
Australia, New South Wales
GSK Investigational Site
Randwick, Sydney, New South Wales, Australia, 2031
Australia, South Australia
GSK Investigational Site
Adelaide, South Australia, Australia, 5000
New Zealand
GSK Investigational Site
Christchurch, New Zealand, 8011
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00359463     History of Changes
Other Study ID Numbers: TRA103452
Study First Received: July 28, 2006
Last Updated: October 25, 2012

Keywords provided by GlaxoSmithKline:
hepatitis C-associated thrombocytopenia
chemotherapy induced thrombocytopenia
hepatic impairment
chronic immune thrombocytopenia purpura

Additional relevant MeSH terms:
Liver Diseases
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Digestive System Diseases
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases processed this record on September 21, 2017